Strides Pharma found destroying, dumping drug production documents: USFDA Investigation
In the letter to Strides Pharma, the FDA didn't explain whether its inspectors often check scrap yards or shredding rooms for documents, or whether it was acting on some kind of tipoff to do so at the Strides plant.
BENGALURU: A U.S. Food and Drug Administration (FDA) investigator discovered that India's Strides Pharma Science Ltd, which exports to the U.S. market, was shredding drug production, quality and laboratory documents and dumping others in a scrapyard.
The "uncontrolled destruction" of manufacturing records and the lack of adequate documentation handling at the drugmaker's factory at Puducherry in southern India, called into question the effectiveness of its quality unit and the integrity and accuracy of its records, the regulator said in a warning letter made public on Tuesday.
The investigator observed multiple bags of manufacturing documents awaiting shredding and a blue binder including the records of batches of drugs produced for the U.S. market in a 55-gallon drum in the scrapyard, Francis Godwin, director of the FDA's Office of Manufacturing Quality, said in the letter here dated July 1.
The potential importance of individual documents wasn't made clear by the FDA.
Strides, which also has factories in Italy, Kenya and Singapore, produces drugs that treat AIDS, malaria and hepatitis. Its revenue grew 6% in the last fiscal year.
In the letter to Strides, the FDA didn't explain whether its inspectors often check scrap yards or shredding rooms for documents, or whether it was acting on some kind of tipoff to do so at the Strides plant.
In its initial response to the FDA's findings, Strides said the discarding of the binder was inadvertent.
The FDA said Strides response was "inadequate" because it did not assess how poor documentation practices affected distributed drug product or how the manufacturer would strengthen its quality unit's oversight.
The agency said it found "significant violations" of current good manufacturing practice (CGMP) regulations at the facility.
Shares of the Bengaluru-based company, which fell as much as 8% to a near one-year low earlier on Wednesday, pared some losses to end 3.4% lower.
Last month, Aurobindo Pharma Ltd was warned here by the FDA for ignoring impurities in an active ingredient it produced. The Hyderabad-based drugmaker recalled contaminated valsartan in January and in March.
"CGMP documents in the binder were dated as recently as January 21, 2019: seven days before our inspection. Your quality unit did not review or check these documents prior to disposal," Godwin said in the letter, addressed to Strides Chief Executive Officer Arun Kumar.
On July 2, Strides shares slumped after it said it received a warning letter from the U.S. FDA, it did not disclose the content of the letter at that time.
A Strides spokesman said on Wednesday the company did not have any further comment.
Strides bought a unit of Vivimed Labs Ltd in January. Vivimed manufactures losartan, a drug that is part of a wider recall in the United States.
The FDA's warning letter comes months after several Indian drugmakers, including Sun Pharmaceutical Ltd and Dr.Reddy's Laboratories Ltd, were named in a U.S. lawsuit against Israeli drugmaker Teva Pharmaceutical Industries Ltd accusing it of conspiring to inflate drug prices and stifle competition for generic drugs.
Reporting by Chandini Monnappa in Bengaluru; editing by Gopakumar Warrier and Rashmi Aich
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here